RxDoctor Payments DataLook up a doctor →

Adam Gerstenblith, MD

Retina Specialist · Hagerstown, MDNPI 1265654875

Payments from drug & device makers

$8,606,254in general payments, 2019–2025

Across 2,653 payments — averaging $3243.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$3.6M
  • Ocular Therapeutix, Inc.$931K
  • Apellis Pharmaceuticals, Inc.$894K
  • Eyepoint US, Inc.$889K
  • Bayer$888K
  • Boehringer Ingelheim$519K
  • plus $841K from 10 others
$1,632in research payments, 2019–2025

Across 1 payment — averaging $1631.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,606,254 in reported general payments places this provider in the 95th percentile of 47 retina specialist providers in Maryland.

See all retina specialist providers in Maryland

Medicare billing

Part B allowed, 2024
$6,370,740
Medicare patients
1,566
Services billed
88,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other retina specialist in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →